Revelation Biosciences Q2 2024 GAAP EPS $(5.13)
Portfolio Pulse from Benzinga Newsdesk
Revelation Biosciences (NASDAQ:REVB) reported a Q2 2024 GAAP EPS loss of $(5.13) per share.
August 09, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Revelation Biosciences reported a significant quarterly loss of $(5.13) per share for Q2 2024, which is likely to negatively impact the stock price in the short term.
The reported loss of $(5.13) per share is a significant negative earnings result, which is likely to lead to a decrease in investor confidence and a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100